We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-8.44%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$139M
AUM Growth
-$143M
Cap. Flow
-$114M
Cap. Flow %
-82.34%
Top 10 Hldgs %
70.94%
Holding
41
New
11
Increased
5
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$5.54M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$3.82M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$2.63M
4
AXSM icon
Axsome Therapeutics
AXSM
+$2.18M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.15M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$37.6M
2
ADVM
Adverum Biotechnologies
ADVM
+$14.1M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.2M
4
VCYT icon
Veracyte
VCYT
+$9.82M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$9.36M

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDMN
1
DELISTED
Kadmon Holdings, Inc.
KDMN
$16.2M 11.66%
6,412,500
-1,205,000
-16% -$2.99M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.93B
$13.2M 9.56%
727,500
-1,699,201
-70% -$37.6M
ARVN icon
3
Arvinas
ARVN
$520M
$12.2M 8.81%
566,500
+15,500
+3% +$380K
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$11.4M 8.26%
150,000
-50,000
-25% -$4.16M
ARWR icon
5
Arrowhead Research
ARWR
$12.1B
$10.9M 7.88%
387,500
-91,000
-19% -$2.69M
AXSM icon
6
Axsome Therapeutics
AXSM
$10.9B
$10.6M 7.63%
522,500
+85,000
+19% +$2.18M
MIST icon
7
Milestone Pharmaceuticals
MIST
$139M
$6.89M 4.97%
369,500
+22,500
+6% +$443K
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.02B
$6.33M 4.57%
702,500
+1,000
+0.1% +$9.46K
CRSP icon
9
CRISPR Therapeutics
CRSP
$4.88B
$5.49M 3.96%
134,000
+55,000
+70% +$2.63M
PTGX icon
10
Protagonist Therapeutics
PTGX
$8.51B
$5.03M 3.63%
418,500
-253,000
-38% -$3.19M
BLU
11
DELISTED
BELLUS Health Inc.
BLU
$5.02M 3.62%
+785,000
New +$5.54M
AUPH icon
12
Aurinia Pharmaceuticals
AUPH
$1.87B
$4.54M 3.28%
850,000
-85,000
-9% -$514K
INSM icon
13
Insmed
INSM
$21.3B
$3.88M 2.8%
220,000
-215,500
-49% -$4.16M
RETA
14
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.61M 2.61%
+45,000
New +$3.82M
VCYT icon
15
Veracyte
VCYT
$3.58B
$2.7M 1.95%
112,500
-369,000
-77% -$9.82M
ARGX icon
16
argenx
ARGX
$52B
$2.56M 1.85%
22,500
-58,500
-72% -$7.91M
KPTI icon
17
Karyopharm Therapeutics
KPTI
$44.6M
$2.29M 1.65%
+15,833
New +$2.15M
IRIX icon
18
IRIDEX
IRIX
$14.4M
$2.17M 1.56%
1,171,300
– –
AMRN
19
Amarin Corp
AMRN
$297M
$1.52M 1.09%
+5,000
New +$1.75M
KURA icon
20
Kura Oncology
KURA
$816M
$1.44M 1.04%
+95,000
New +$1.69M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.32M 0.96%
17,000
-45,500
-73% -$4.27M
ZYME icon
22
Zymeworks
ZYME
$1.6B
$1.3M 0.94%
+52,500
New +$1.32M
RARX
23
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.3M 0.94%
+55,000
New +$1.63M
ASMB icon
24
Assembly Biosciences
ASMB
$503M
$1.29M 0.93%
10,958
-2,209
-17% -$334K
MRUS
25
DELISTED
Merus
MRUS
$1.23M 0.89%
+69,274
New +$1.14M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Acuta Capital Partners held 41 positions worth $139M, down 51% from $281M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Acuta Capital Partners withdrew a net $114M in Q3 2019, closing 10 positions and reducing 13 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $14.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in BELLUS Health Inc. worth $5.02M.

  • Acuta Capital Partners's largest Q3 2019 buy was BELLUS Health Inc.: 785,000 shares worth $5.02M.
  • Acuta Capital Partners added most to CRISPR Therapeutics in Q3 2019, an estimated $2.63M increase.
  • Acuta Capital Partners's biggest Q3 2019 reduction was Iovance Biotherapeutics, cutting an estimated $37.6M.
  • Acuta Capital Partners fully exited Adverum Biotechnologies in Q3 2019, selling an estimated $14.1M.
  • Acuta Capital Partners's ten largest holdings make up 71% of its $139M portfolio in Q3 2019.
  • Acuta Capital Partners opened 11 new positions and closed 10 in Q3 2019.
  • Acuta Capital Partners's portfolio value fell 51% quarter-over-quarter to $139M.

Based on Acuta Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.